8-K
filed September 1, 2026, 9:26 AM ET
ticker CRNX
CIK 0001658247
M&A
confidence high
sentiment neutral
materiality 1.00
Crinetics completes $10B acquisition by Vertex at $85/share
Crinetics Pharmaceuticals, Inc.
- Merger completed Sept 1, 2026; Crinetics shareholders receive $85.00 per share cash.
- Aggregate consideration ~$10.0B, funded via Vertex cash and term loan borrowings.
- Crinetics common stock to be delisted from Nasdaq; Form 25 and Form 15 filings to follow.
- All prior directors resigned; Charles Wagner named sole director and President; Prasanna Thombre and Omar White as Treasurer and Secretary.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Rogério Vivaldi Coelho resigned as Director at Crinetics Pharmaceuticals, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
each of the directors of the Company, R. Scott Struthers, Ph.D., Camille L. Bedrosian, M.D., Caren Deardorf, Matthew K. Fust, Weston Nichols, Ph.D., Stephanie S. Okey, M.S., Rogério Vivaldi Coelho, M.D. and Wendell Wierenga, Ph.D., resigned and ceased to be a director of the Company and a member of any committee of the Company’s Board of Directors.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Charles Wagner was appointed as Director at Crinetics Pharmaceuticals, Inc..
- Action
- became
- Role
- Director
Exact text from the filing
the sole director of Merger Sub immediately prior to the Effective Time became the sole director of the Surviving Corporation. The sole director of Merger Sub immediately prior to the Effective Time was Charles Wagner.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Caren Deardorf resigned as Director at Crinetics Pharmaceuticals, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
each of the directors of the Company, R. Scott Struthers, Ph.D., Camille L. Bedrosian, M.D., Caren Deardorf, Matthew K. Fust, Weston Nichols, Ph.D., Stephanie S. Okey, M.S., Rogério Vivaldi Coelho, M.D. and Wendell Wierenga, Ph.D., resigned and ceased to be a director of the Company and a member of any committee of the Company’s Board of Directors.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Charles Wagner was appointed as President at Crinetics Pharmaceuticals, Inc..
- Action
- became
- Role
- President
Exact text from the filing
In connection with the consummation of the Merger, as of immediately after the Effective Time, Charles Wagner, Prasanna Thombre and Omar White became the President, Treasurer and Secretary of the Surviving Corporation, respectively.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Prasanna Thombre was appointed as Treasurer at Crinetics Pharmaceuticals, Inc..
- Action
- became
- Role
- Treasurer
Exact text from the filing
In connection with the consummation of the Merger, as of immediately after the Effective Time, Charles Wagner, Prasanna Thombre and Omar White became the President, Treasurer and Secretary of the Surviving Corporation, respectively.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
R. Scott Struthers resigned as Director at Crinetics Pharmaceuticals, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
each of the directors of the Company, R. Scott Struthers, Ph.D., Camille L. Bedrosian, M.D., Caren Deardorf, Matthew K. Fust, Weston Nichols, Ph.D., Stephanie S. Okey, M.S., Rogério Vivaldi Coelho, M.D. and Wendell Wierenga, Ph.D., resigned and ceased to be a director of the Company and a member of any committee of the Company’s Board of Directors.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Stephanie S. Okey resigned as Director at Crinetics Pharmaceuticals, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
each of the directors of the Company, R. Scott Struthers, Ph.D., Camille L. Bedrosian, M.D., Caren Deardorf, Matthew K. Fust, Weston Nichols, Ph.D., Stephanie S. Okey, M.S., Rogério Vivaldi Coelho, M.D. and Wendell Wierenga, Ph.D., resigned and ceased to be a director of the Company and a member of any committee of the Company’s Board of Directors.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Weston Nichols resigned as Director at Crinetics Pharmaceuticals, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
each of the directors of the Company, R. Scott Struthers, Ph.D., Camille L. Bedrosian, M.D., Caren Deardorf, Matthew K. Fust, Weston Nichols, Ph.D., Stephanie S. Okey, M.S., Rogério Vivaldi Coelho, M.D. and Wendell Wierenga, Ph.D., resigned and ceased to be a director of the Company and a member of any committee of the Company’s Board of Directors.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Omar White was appointed as Secretary at Crinetics Pharmaceuticals, Inc..
- Action
- became
- Role
- Secretary
Exact text from the filing
In connection with the consummation of the Merger, as of immediately after the Effective Time, Charles Wagner, Prasanna Thombre and Omar White became the President, Treasurer and Secretary of the Surviving Corporation, respectively.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Matthew K. Fust resigned as Director at Crinetics Pharmaceuticals, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
each of the directors of the Company, R. Scott Struthers, Ph.D., Camille L. Bedrosian, M.D., Caren Deardorf, Matthew K. Fust, Weston Nichols, Ph.D., Stephanie S. Okey, M.S., Rogério Vivaldi Coelho, M.D. and Wendell Wierenga, Ph.D., resigned and ceased to be a director of the Company and a member of any committee of the Company’s Board of Directors.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Camille L. Bedrosian resigned as Director at Crinetics Pharmaceuticals, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
each of the directors of the Company, R. Scott Struthers, Ph.D., Camille L. Bedrosian, M.D., Caren Deardorf, Matthew K. Fust, Weston Nichols, Ph.D., Stephanie S. Okey, M.S., Rogério Vivaldi Coelho, M.D. and Wendell Wierenga, Ph.D., resigned and ceased to be a director of the Company and a member of any committee of the Company’s Board of Directors.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Wendell Wierenga resigned as Director at Crinetics Pharmaceuticals, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
each of the directors of the Company, R. Scott Struthers, Ph.D., Camille L. Bedrosian, M.D., Caren Deardorf, Matthew K. Fust, Weston Nichols, Ph.D., Stephanie S. Okey, M.S., Rogério Vivaldi Coelho, M.D. and Wendell Wierenga, Ph.D., resigned and ceased to be a director of the Company and a member of any committee of the Company’s Board of Directors.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.